Springer G F, Desai P R, Ghazizadeh M, Tegtmeyer H
Heather M. Bligh Cancer Research Laboratories, Chicago Medical School, IL 60064, USA.
Cancer Detect Prev. 1995;19(2):173-82.
Pathogenetic aspects of pancarcinoma T/Tn autoantigens were investigated; they are present in approximately 90% of all carcinomas from incipience and throughout. T/Tn are occluded in noncarcinoma (non-CA) diseased and healthy tissues. By serological and immunohistochemical methods, we found that well-differentiated carcinomata express a higher proportion of T than Tn, while in poorly differentiated carcinomata, Tn predominates over T. Tn density of primary carcinomas correlates positively with aggressiveness, early clinical relapse, and early death. Delayed-type skin hypersensitivity to T (DTHR-T) and solid-phase anti-T antibody immunoassay (SPIA-T), respectively, detected 85% of 461 and 88% of 222 carcinoma patients; < 7% of over 450 benign diseased and healthy subjects reacted positively in these assays. T/anti-T assays are highly effective in detecting incipient (TisN0M0 and T1N0M0) carcinomas: DTHR-T-85% of 41, and SPIA-T-96% of 26 patients. Positive anti-T tests predicted CA in 74% of 47 patients months to years before their biopsy/X-ray turned positive.
对全癌T/Tn自身抗原的发病机制进行了研究；它们在所有癌症从发病开始直至整个病程中约90%的病例中都存在。T/Tn在非癌（非CA）病变组织和健康组织中被封闭。通过血清学和免疫组化方法，我们发现高分化癌中T的表达比例高于Tn，而在低分化癌中，Tn的表达超过T。原发性癌的Tn密度与侵袭性、早期临床复发和早期死亡呈正相关。对T的迟发型皮肤超敏反应（DTHR-T）和固相抗T抗体免疫测定（SPIA-T）分别在461例癌症患者中检测出85%，在222例患者中检测出88%；在450多名良性病变和健康受试者中，<7%的人在这些检测中呈阳性反应。T/抗T检测在检测早期（TisN0M0和T1N0M0）癌方面非常有效：DTHR-T在41例患者中检测出85%，SPIA-T在26例患者中检测出96%。抗T检测呈阳性在47例患者活检/X光检查呈阳性前数月至数年就预测出癌症，准确率达74%。
